Loading
People with an inherited TP53 mutation face a near-certain lifetime cancer risk. Yearly whole-body MRI catches cancers early; adding blood DNA tests may catch them earlier still.
People with an inherited TP53 mutation face a near-certain lifetime cancer risk, so this idea builds a global Li-Fraumeni registry with standardised whole-body MRI surveillance plus prospective cell-free DNA and fragmentomics testing, to learn whether blood adds lead time over imaging. The Toronto Protocol of whole-body MRI, brain MRI and ultrasound already improved outcomes, the very high prior probability makes positive predictive value acceptable, and the multiplicity of tumour types favours a tumour-agnostic blood test. The test follows a 1,000-carrier prospective cohort for five years. At early-clinical maturity it addresses the bottlenecks Inherited risk is mostly unidentified and The hardest cancers are found late.
One bottleneck page and 15 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
This paper is the reason TP53 status, MDM2 amplification and CDKN2A loss are read together in tumour genomes. It frames the current drug development around MDM2 inhibitors and mutant p53 reactivators as attempts to restore a network rather than a single protein.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified, TP53.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified.
Shares Vogelstein, Lane and Levine 2000: surfing the p53 network, Inherited risk is mostly unidentified, TP53.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified.